FindTrial
Sign In

Real-World effectiveness Following Treatment with Pegylated-Interferon Alpha-2a Compared with Alpha-2b, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3 after entering Thai National Drug List

Real-World effectiveness Following Treatment with Pegylated-Interferon Alpha-2a Compared with Alpha-2b, Both with Ribavirin, for Chronic Hepatitis C Infection with Genotypes 2 and 3 after entering Thai National Drug List.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20200313004
Enrollment
Unknown
Registered
2020-03-13
Start date
2017-07-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intention to treat analysis of SVR vs treatment failure according to treatment response at various time points during treatment. Chronic hepatitis C&#44

Interventions

Intention to treat analysis of SVR vs treatment failure according to treatment response at various time points during treatment,Sustained virological response rate (SVR&#44
%) compare between peginterferon alfa (PEG&#45
IFα) 2a and 2b.
Treatment,Treatment
Treatment,SVR

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Has the following rules 1. Age 18-65 years 2. Viral load (HCV-RNA) more than 5000 IU / ml 3. Only species 2 and 3 4. Enzyme levels (alanine aminotransferase = ALT) from 1.5 times or more 5. Pathology in the liver From the liver puncture Or transient elastography equal to F2 6. Must not be treated with pegylated interferon and ribavirin 7. No joint diseases such as AIDS, kidney failure, renal impairment 8. Disease must be under control. 9. If cirrhosis, must be cirrhosis with Child Pugh score A (5-6).

Exclusion criteria

Exclusion criteria: no

Design outcomes

Primary

MeasureTime frame
Effectiveness of treatment 3 year Compiled from the medical records of patients with chronic hepatitis C virus in all 3 funds that hav—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public ContactWattana Sukeepaisarnjaroen

Khonkaen University

wattanasukee@gmail.com0873731133

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026